Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
185.94(c) 178.8(c) 185.5(c) 186.69(c) 190.77(c) Last
11 402 288 7 179 275 7 303 875 4 413 184 6 553 224 Volume
+11.74% -3.84% +3.75% +0.64% +2.19% Change
More quotes
Financials (USD)
Sales 2020 24 408 M - -
Net income 2020 5 802 M - -
Net Debt 2020 11 301 M - -
P/E ratio 2020 30,0x
Yield 2020 1,56%
Sales 2021 27 490 M - -
Net income 2021 7 055 M - -
Net Debt 2021 9 258 M - -
P/E ratio 2021 24,6x
Yield 2021 1,75%
Capitalization 173 B 173 B -
EV / Sales 2020 7,55x
EV / Sales 2021 6,63x
Nbr of Employees 33 625
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both... 
Sector
Pharmaceuticals
Calendar
01/29Earnings Release
More about the company
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
All news about ELI LILLY AND COMPANY
01/16ELI LILLY AND : Insider at Eli Lilly (LLY) Makes Significant Sale of Stock
MT
01/15ELI LILLY AND : Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 ..
PR
01/15ELI LILLY AND COMPANY : - Gabrielle Sulzberger Elected to Lilly Board of Directo..
AQ
01/15ELI LILLY AND : Lilly Invests $30 Million in Venture Fund for Underrepresented F..
DJ
01/15ELI LILLY AND : Invests $30 Million in Venture Capital Fund Targeting Early-Stag..
MT
01/14INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Eli Lilly
MT
01/14ELI LILLY & CO : Change in Directors or Principal Officers, Financial Statements..
AQ
01/14ELI LILLY AND : Gabrielle Sulzberger Elected to Lilly Board of Directors
PR
01/14ELI LILLY AND : (LLY) sees Significant Insider Selling
MT
01/13Equities End Mixed as House Votes on Impeaching President Trump for Second Ti..
MT
01/12INSIDER TRENDS : Insider Sales Continue 90-Day Trend at Eli Lilly
MT
01/12ELI LILLY AND : Thinking about trading options or stock in Blink Charging, Tesla..
PR
01/12ELI LILLY AND COMPANY : - US FDA accepts supplemental New Drug Application for J..
AQ
01/12ELI LILLY AND COMPANY : - Lilly's Donanemab Slows Clinical Decline of Alzheimer'..
AQ
01/12Eli Lilly, Innovent Filing of Supplemental New Drug Application for Lung Canc..
MT
More news
News in other languages on ELI LILLY AND COMPANY
01/14PORTEFEUILLES : des nouvelles des sélections
01/12Mais qui tire les ficelles ?
01/12EN DIRECT DES MARCHES : Atos, Veolia, Europcar, Solutions 30, CGG, Eli Lilly, Fo..
01/11MÄRKTE USA/Wall Street startet mit Abschlägen in die neue Woche
01/11MÄRKTE USA/Leichte Gewinnmitnahmen belasten Börsen
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 181,58 $
Last Close Price 190,77 $
Spread / Highest target 19,0%
Spread / Average Target -4,82%
Spread / Lowest Target -37,1%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY12.99%172 949
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993